Cumberland Pharmaceuticals Inc Reports Q3 2026 Revenue of $2.2 Million and Net Income of $77. ...
Divestiture Gain Drives Quarterly Profit as Company Pivots to Clinical-Stage Development and Prepares Ifetroban NDA for Duchenne Muscular Dystrophy Related Stocks: CPIX ,